Antibacterial agent 344
Antibacterial agent 344 is an antibacterial agent with potent biofilm inhibition (IC50 = 0.27 μM). Antibacterial agent 344 inhibits heme oxygenase (HemO), impairs iron homeostasis, virulence factor production, and motility. Antibacterial agent 344 synergizes with Ciprofloxacin (HY-B0356) and Tobramycin (HY-B0441), enhancing their efficacy and delaying the development of resistance. Antibacterial agent 344 improves bacterial-infected Galleria mellonella survival, and reduces bacterial load in mice wounds. Antibacterial agent 344 can be used for the research of Pseudomonas aeruginosa infections.
For research use only. We do not sell to patients.
- Formula: C18H14N4O3S2
- Molecular Weight:398.46
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Antibacterial agent 344 (Compound 4p) (0.125-2 μM; 16 h) reduces biofilm, elastase production and iron acquisition in Pseudomonas aeruginosa PAO1 in a concentration-dependent manner[1].
Antibacterial agent 344 binds to HemO protein with a Kd of 269.7 nM[1].
Antibacterial agent 344 shows antibiofilm activity against Pseudomonas aeruginosa PA0405, PA0319, PA0730, PA0209, and PA092 with IC50 values of 0.99-7.87 μM[1].
Antibacterial agent 344 shows synergistic effects of with Ciprofloxacin (HY-B0356) and Tobramycin (HY-B0441)[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Antibacterial agent 344 (2 μM; topical; once daily; 9 days) reduces P. aeruginosa PAO1 bacterial load and accelerates wound healing in mouse wound infections when co-administered with ciprofloxacin or tobramycin, without causing detectable organ toxicity[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:monas aeruginosa wound infected BALB/c mice (female, 3-5 weeks old)[1]
-
Dosage:2 μM
-
Administration:topical; once daily; 9 days
-
Result:Reduced bacterial load by 2.10 log10 CFU compared to the control and 1.37 log10 CFU compared to ciprofloxacin monotherapy when combined with 0.0008 mg/mL Ciprofloxacin.
Accelerated wound healing compared to control and Ciprofloxacin monotherapy when combined with 0.0008 mg/mL ciprofloxacin.
Reduced bacterial load by 2.11 log10 CFU compared to the control and relative to Tobramycin monotherapy when combined with 0.002 mg/mL Tobramycin.
Accelerated wound healing compared to control and Tobramycin monotherapy when combined with 0.002 mg/mL tobramycin.
Caused no histopathological alterations in heart, liver, spleen, lung, or kidney tissues.
Caused no significant body weight changes.
Chemical Information
-
Molecular Weight 398.46
-
Formula C18H14N4O3S2
-
SMILES
O=C(CN1N=NC(CSC2=NC3=C(S2)C=CC=C3)=C1)C4=CC=C(C(O)=C4)O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Antibacterial agent 344 Related Classifications
HY-183711 Related Classifications
Powered by Bioz
- Antibacterial agent 344
- Antibacterial agent344
- Antibacterial agent-344
- Bacterial
- Heme Oxygenase (HO)
- Pseudomonas aeruginosa PAO1
- Galleria mellonella
- elastase
- mouse wound infections
- heme iron acquisition
- biofilm formation
- HemO
- virulence factor production
- iron homeostasis
- Pseudomonas aeruginosa
- Inhibitor
- inhibitor
- inhibit